Log in

TSE:CTX - Crescita Therapeutics Stock Price, Forecast & News

-0.03 (-5.45 %)
(As of 04/3/2020 01:16 AM ET)
Today's Range
Now: C$0.52
50-Day Range
MA: C$0.79
52-Week Range
Now: C$0.52
Volume33,552 shs
Average Volume43,543 shs
Market CapitalizationC$10.93 million
P/E Ratio5.98
Dividend YieldN/A
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, Europe, the United States, and internationally. It owns various proprietary drug delivery platforms, including DuraPeel and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; Flexicaine, an anesthetic formulation of lidocaine and tetracaine for the topical treatment of pain conditions; MiCal 1 that is in Phase II clinical trial for the treatment of moderate to severe plaque psoriasis; and MiCal 2, which is in preclinical stage to treat a dermatological skin condition. Its non-prescription skincare products comprise skincare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of cosmeceutical products for anti-aging medical procedures under the Pro-Derm brand; anti-aging skincare products to consumers of 35 years of age and over under the Premiology brand; a line of products to target and treat various skincare concerns under the Alyria brand; and a range of skincare products for hydration, sun care, atopic dermatitis, baby skin, acne, women's health, and sun damage repair under the ISDIN brand. The company also offers contract manufacturing services. Crescita Therapeutics Inc. has a collaboration agreement with Tetra Natural Health to develop Tetra's dermatology portfolio using the company's transdermal delivery technologies, multiplexed molecular penetration enhancer and DuraPeel. The company was incorporated in 2016 and is headquartered in Laval, Canada.
Read More

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$22.34 million
Cash FlowC$0.41 per share
Book ValueC$1.02 per share



Market CapC$10.93 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.

Crescita Therapeutics (TSE:CTX) Frequently Asked Questions

How has Crescita Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Crescita Therapeutics' stock was trading at C$0.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTX shares have decreased by 35.0% and is now trading at C$0.52. View which stocks have been mosted impacted by Coronavirus.

Has Crescita Therapeutics been receiving favorable news coverage?

Media headlines about CTX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crescita Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutCrescita Therapeutics.

Who are some of Crescita Therapeutics' key competitors?

What other stocks do shareholders of Crescita Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crescita Therapeutics investors own include CBTX (CBTX), WEST JAPAN RWY/S (WJRYY), FAT Brands (FAT), Tesla (TSLA), Laredo Petroleum (LPI), Spirit AeroSystems (SPR), Wells Fargo & Co (WFC), Contango Oil & Gas (MCF), North American Construction Group (NOA) and ConvaTec Group (CTEC).

Who are Crescita Therapeutics' key executives?

Crescita Therapeutics' management team includes the following people:
  • Mr. Daniel N. Chicoine B.Comm., CPA, CA, Exec. Chairman
  • Mr. Serge Verreault B.A., M.B.A., Pres & CEO
  • Mr. Jose DaRocha C.A., CPA, Chief Financial Officer
  • Mr. François Woods, VP of Sales & Marketing
  • Dominic King-Smith, VP of Bus. Devel.

What is Crescita Therapeutics' stock symbol?

Crescita Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CTX."

How do I buy shares of Crescita Therapeutics?

Shares of CTX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Crescita Therapeutics' stock price today?

One share of CTX stock can currently be purchased for approximately C$0.52.

How big of a company is Crescita Therapeutics?

Crescita Therapeutics has a market capitalization of C$10.93 million and generates C$22.34 million in revenue each year. Crescita Therapeutics employs 62 workers across the globe. View additional information about Crescita Therapeutics.

What is Crescita Therapeutics' official website?

The official website for Crescita Therapeutics is http://www.crescitatherapeutics.com/.

How can I contact Crescita Therapeutics?

Crescita Therapeutics' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The company can be reached via phone at +1-905-6734295.

MarketBeat Community Rating for Crescita Therapeutics (TSE CTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Crescita Therapeutics and other stocks. Vote "Outperform" if you believe CTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel